Sepideh Mohammadipour
@sepidemoh
Radiation Oncology Resident
Hacettepe University
ID: 1919404300385587200
05-05-2025 14:50:31
0 Tweet
2 Followers
31 Following
👉🏻 Our new publication suggests no survival benefit from adding CHT to RT in stage II NPC 👉🏻 While RT alone was effective overall, selected patients might still benefit from tailored use of CHT⁉️ 👉🏻 CONC: More data needed ✅ Melek Tugce Yilmaz MD Sepideh Mohammadipour onkder.org/abstract.php?l…
